Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

BMC Infectious Diseases

Table 3 Annual number of disease cases in canada under each vaccine program

Program	IPD		PNE		AOM
	Bacteremia	Meningitis	In-patient	Out-patient	Mild	Moderate/Severe
Direct and indirect effects
PCV13	10,427	368	101,325	257,356	762,343	118,999
PCV10	14,511	512	110,085	263,557	789,344	122,150
Direct effects only
PCV13	14,459	510	108,785	262,485	785,018	121,437
PCV10	14,511	512	110,085	263,557	789,344	122,150

AOM acute otitis media; IPD invasive pneumococcal disease; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.

ISSN: 1471-2334